抗菌药物敏感性试验方法的修改原则
本文讨论新抗菌药物研发中抗菌药物敏感性试验(AST)方法的建立与修改问题。标准参考方法为阳离子调节MH肉汤微量稀释法(CAMHB),CLSI M07与ISO 20776-1予以定义。CLSI与EUCAST强调,偏离参考方法须有科学依据,仅为降低MIC或使某药显得更优的修改不科学且应强烈反对。
要点
- AST标准参考方法为CAMHB微量稀释法,依据CLSI M07与ISO 20776-1。
- 方法修改须有科学依据,能更好反映临床疗效。
- 仅为降低MIC或使某药显得更优的修改不科学,应强烈反对。
核心结论
- 新抗菌药物应尽早建立可靠的AST方法,以确保患者及时获得药物。
- 对参考AST方法的修改必须有科学依据,不得仅为降低MIC或使某药显得更优。
- CLSI与EUCAST联合指南定稿前,应尽早用参考方法进行严格评估。
研究设计与样本
- 本文为方法学论述,非原始研究,未报告样本量或研究设计细节。
主要发现
- 标准参考AST方法为CAMHB微量稀释法,由CLSI M07与ISO 20776-1定义。
- 某些药物可能需修改参考方法以更好反映临床活性,但修改须有科学依据。
- 仅为产生更低MIC值或使某药显得优于其他药的修改不科学且应强烈反对。
- CLSI与EUCAST警告,不必要偏离参考AST方法可增加成本、监管障碍、延迟检测可用性并降低临床采用。
关键数值与推荐
- 参考方法:CAMHB微量稀释法(CLSI M07第12版,2024;ISO 20776-1,2019)。
- CLSI与EUCAST正在制定联合指南,尚未定稿。
临床怎么用
- 新抗菌药物研发早期应建立并严格评估基于参考方法的AST。
- 修改AST方法须提供科学依据,避免仅为降低MIC或优化药物表象的偏离。
局限性
- 本文为观点性论述,未报告原始研究数据或系统评价结果。
- CLSI与EUCAST联合指南尚在制定中,相关建议可能更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of new antimicrobial agents is essential to combat antimicrobial resistance. Reliable antimicrobial susceptibility testing (AST) methods should be established early and thoughtfully to ensure timely patient access to these agents. The standard reference method for AST is broth microdilution (BMD) in cation-adjusted Mueller-Hinton broth (CAMHB), as defined by CLSI M07 (CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 12th ed. CLSI Standard M07. Clinical and Laboratory Standards Institute, 2024) and ISO 20776-1 (ISO. Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices-Part 1: Broth Micro-dilution Reference Method for Testing the In Vitro Activity of Antimicrobial Agents Against Rapidly Growing Aerobic Bacteria Involved in Infectious Diseases. ISO 20776-1. International Organization for Standardization, 2019). While some agents may require modifications to this method to better reflect clinical activity, such changes must be scientifically justified. Modifications aimed solely at producing lower minimal inhibitory concentration (MIC) values-or to make one antimicrobial agent appear superior to others-are not scientifically valid and are strongly discouraged. Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) caution developers that unnecessary deviations from reference AST methods can lead to increased costs, regulatory hurdles, delays in test availability and reduced clinical adoption. Until joint guidance under development by CLSI and EUCAST is finalized, early and rigorous evaluation using the reference method is essential.
引用
- Morrissey I, Patel JB. Modification of antimicrobial susceptibility testing methods. J Antimicrob Chemother. 2025. PMID: 40971802. doi:10.1093/jac/dkaf332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。